Pityriasis rosea is a papulosquamous skin disorder that occurs most commonly between the ages of 10 and 35 years. Recurrent pityriasis rosea is rare. We report a patient suffering from recurrent pityriasis rosea, whose etiology may be related to either vaccine-induced stimulation of the immune system, or some rare vaccine component(influenza A [H1N1] vaccine, hepatitis B vaccine). We believe that such a case is unique and it has not been reported previously. The patient was successfully treated with a combination of oral cetirizine, a topical steroid cream, and narrowband-ultraviolet B phototherapy. The symptoms of this disorder should be recognized by dermatologists.
CITATION STYLE
Li, A., Li, P., Li, Y., & Li, W. (2018). Recurrent pityriasis rosea: A case report. Human Vaccines and Immunotherapeutics, 14(4), 1024–1026. https://doi.org/10.1080/21645515.2017.1409928
Mendeley helps you to discover research relevant for your work.